Cargando…

Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays

Real-time quantitative reverse transcriptase polymerase chain reaction (rRT-PCR) is now widely used to detect viral pathogens in various human specimens. The application of internal controls to validate the entire process of these assays is necessary to prevent false-negative results caused by unexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xueliang, Liu, Fen, Jiang, Lingli, Bao, Yun, Xiao, Yanqun, Wang, Hualiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080162/
https://www.ncbi.nlm.nih.gov/pubmed/26474983
http://dx.doi.org/10.1007/s00253-015-7042-y
_version_ 1783507973068292096
author Wang, Xueliang
Liu, Fen
Jiang, Lingli
Bao, Yun
Xiao, Yanqun
Wang, Hualiang
author_facet Wang, Xueliang
Liu, Fen
Jiang, Lingli
Bao, Yun
Xiao, Yanqun
Wang, Hualiang
author_sort Wang, Xueliang
collection PubMed
description Real-time quantitative reverse transcriptase polymerase chain reaction (rRT-PCR) is now widely used to detect viral pathogens in various human specimens. The application of internal controls to validate the entire process of these assays is necessary to prevent false-negative results caused by unexpected inhibition or inefficient extraction. In the present study, we describe a strategy to produce a stable internal control for rRT-PCR by packaging foreign RNA into influenza virions using plasmid-based reverse genetics technology. The envelope structure of influenza virus can effectively protect RNA segments from RNase digestion, which provides an advantage for its routine use as an internal control. Utilizing this approach, we successfully generated a recombinant influenza virus (rPR8-HCV) containing the 5′ untranslated region (5′ UTR) of the hepatitis C virus (HCV) RNA genome. After inactivation and purification, the rPR8-HCV particles were demonstrated to be RNase resistant and stable at 4 °C for at least 252 days in human plasma, with no degradation even after being frozen and thawed multiple times. These results were reproducible in the COBAS TaqMan HCV test for 164 days. Moreover, the chimeric influenza virus particles could be easily produced in embryonated eggs and were noninfectious after inactivation treatment. Additionally, this strategy could also be adapted for real-time clinical applications of other RNA targets, providing a universal approach with broad clinical applications in rRT-PCR assays.
format Online
Article
Text
id pubmed-7080162
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70801622020-03-23 Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays Wang, Xueliang Liu, Fen Jiang, Lingli Bao, Yun Xiao, Yanqun Wang, Hualiang Appl Microbiol Biotechnol Biotechnological Products and Process Engineering Real-time quantitative reverse transcriptase polymerase chain reaction (rRT-PCR) is now widely used to detect viral pathogens in various human specimens. The application of internal controls to validate the entire process of these assays is necessary to prevent false-negative results caused by unexpected inhibition or inefficient extraction. In the present study, we describe a strategy to produce a stable internal control for rRT-PCR by packaging foreign RNA into influenza virions using plasmid-based reverse genetics technology. The envelope structure of influenza virus can effectively protect RNA segments from RNase digestion, which provides an advantage for its routine use as an internal control. Utilizing this approach, we successfully generated a recombinant influenza virus (rPR8-HCV) containing the 5′ untranslated region (5′ UTR) of the hepatitis C virus (HCV) RNA genome. After inactivation and purification, the rPR8-HCV particles were demonstrated to be RNase resistant and stable at 4 °C for at least 252 days in human plasma, with no degradation even after being frozen and thawed multiple times. These results were reproducible in the COBAS TaqMan HCV test for 164 days. Moreover, the chimeric influenza virus particles could be easily produced in embryonated eggs and were noninfectious after inactivation treatment. Additionally, this strategy could also be adapted for real-time clinical applications of other RNA targets, providing a universal approach with broad clinical applications in rRT-PCR assays. Springer Berlin Heidelberg 2015-10-16 2016 /pmc/articles/PMC7080162/ /pubmed/26474983 http://dx.doi.org/10.1007/s00253-015-7042-y Text en © Springer-Verlag Berlin Heidelberg 2015 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Biotechnological Products and Process Engineering
Wang, Xueliang
Liu, Fen
Jiang, Lingli
Bao, Yun
Xiao, Yanqun
Wang, Hualiang
Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title_full Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title_fullStr Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title_full_unstemmed Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title_short Use of chimeric influenza viruses as a novel internal control for diagnostic rRT-PCR assays
title_sort use of chimeric influenza viruses as a novel internal control for diagnostic rrt-pcr assays
topic Biotechnological Products and Process Engineering
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080162/
https://www.ncbi.nlm.nih.gov/pubmed/26474983
http://dx.doi.org/10.1007/s00253-015-7042-y
work_keys_str_mv AT wangxueliang useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays
AT liufen useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays
AT jianglingli useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays
AT baoyun useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays
AT xiaoyanqun useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays
AT wanghualiang useofchimericinfluenzavirusesasanovelinternalcontrolfordiagnosticrrtpcrassays